MRUS MERUS B V

Merus to Present at BofA Securities 2025 Health Care Conference

Merus to Present at BofA Securities 2025 Health Care Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET.

The webcast of the presentation will be contemporaneously available on the of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus

is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit and .

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
 

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
EN
08/05/2025

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

 PRESS RELEASE
Free
MRUS MERUS B V

Merus to Present at BofA Securities 2025 Health Care Conference

Merus to Present at BofA Securities 2025 Health Care Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET. The webcast of the presentation will be contemporaneously available on the of the Company'...

6h / 43m 1 EN
Thomas Vranken
  • Thomas Vranken
MRUS MERUS B V

Merus FIRST LOOK: 1Q25 results as expected, looking out toward ASCO up...

Merus announced its 1Q25 results, highlighting ongoing clinical trials and financial performance. The Ph2 trial of Peto in combination with Keytruda for head and neck cancer is progressing, with an update expected at ASCO 2025. The two Ph3 trials for head and neck cancer continue enrolling, with substantial enrolment expected by year-end 2025. With $ 638m in cash, Merus reiterates its cash runway into 2028. We reiterate our $ 59 TP/Buy.

11h / 41m 11h / 41m 1 EN
Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
SOLB SOLVAY SA
ZLDPF Zealand Pharma ... ... (+9)

Morning Notes : ABI BB, ARGX BB, ATEB BB, CPINV BB, SOLB BB, CTPNV NA,...

: ABI BB, ARGX BB, ATEB BB, CPINV BB, SOLB BB, CTPNV NA, ZEAL DC, JDEP NA, MRUS US

SOLB SOLVAY SA
ZLDPF ZEALAND PHARMA A/S
CPINV CARE PROPERTY INVEST SA
ATEB ATENOR S.A.
ABI ANHEUSER-BUSCH INBEV SA/NV
MRUS MERUS B V
ARGX ARGEN-X SE
JDEP JDE PEET'S NV
CTPNV CTP NV
11h / 47m 11h / 47m 1 EN
Guy Sips ... (+13)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
BEKB BEKAERT SA
DIE D'IETEREN SA ... (+12)

Dynamic Top Pick List Update May 2025: Removing Fugro – Adding Merus

The ongoing tariff war continues to create uncertainty for investors, with a trade embargo between the US and China. Although Europe has received a temporary reprieve, the prolonged situation could result in significant economic damage. We are maintaining a defensive stance in our Benelux Dynamic Top Pick List, as the Federal Reserve holds steady and the European Central Bank may continue lowering rates. Pessimism regarding the European industry has increased, though some US-based European compa...

BEKB BEKAERT SA
DIE D'IETEREN SA
SOF SOFINA SA
ROYAL VOPAK NV
MELE MELEXIS NV
MRUS MERUS B V
ADYEN ADYEN NV
WDP WAREHOUSES DE PAUW SCA
FUR FUGRO NV
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
12h / 43m 12h / 43m 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus Announces Financial Results for the First Quarter 2025 and Provi...

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific ant...

22h / 31m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch